Durham Community Low Vision Center

October 19, 2017

Community Low Vision Center
New To Durham!

Join us for an Open House
to celebrate the opening of our
Community Low Vision Center.

Thursday, October 26, 2017 from 5:30-7:30 pm
Community Low Vision Center
Erwin Terrace
2816 Erwin Road, Suite 201
Durham, NC 27705

light hors d’oeurves served with beer & wine

Helping preserve & create independent
lifestyles for persons with all levels of low vision.

RSVP to marketing@ifbsolutions.org or
Barbara Soderlund at 336-245-5691


New Drug Slows Dry Macular Degeneration

October 14, 2017

An international team of researchers has found a way to slow the progression of an advanced form of age-related macular degeneration (AMD), a leading cause of irreversible, severe vision loss in Western countries.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a platform of novel therapeutic compounds for the treatment of autoimmune diseases, developed a new compound called the complement factor 3 (C3) inhibitor APL-2 for treating patients with dry AMD.

The Phase II FILLY trial of APL-2 was sponsored by Apellis Pharmaceuticals and included 246 patients across 40 testing sites, in the United States, Australia and New Zealand.

“These results are very exciting for all people afflicted with dry AMD,” said team member Dr. David Boyer, of Retina-Vitreous Associates Medical Group.

“It is currently an untreatable condition, and the reduction of the progression of atrophy in this trial offers new hope for vision maintenance for our patients.”

for more info:



Duke Eye Center Low-Vision Demo

October 14, 2017

This is a quick reminder that we will have an updated assistive technology demonstration at the Duke Eye Center Low-Vision Clinic on Friday, October 20th at 3:30.

As you walk in to the door to the Duke Eye Center from the parking lot, take the first door to the left to get to the low-vision clinic. Ask for Fay Tripp and she will take you to the conference room where the demonstration will be held.

I should also mention that the new Community Low Vision Center is located 3 blocks from the Duke Eye Center. If you have time, it would be nice for you to visit there, while you’re in the area.

Looking forward to seeing you all there. My cell phone is 919-923-6080, you can contact me if you have questions.

We will need an RSVP if you plan to come to the October 20th 3:30 AT demonstration at Duke Eye Center. If you plan to come please contact laurenandjay@mindspring.com. There will be limited space.

Lauren Tappan

New Low Vision Center

October 5, 2017

There is a new Community Low Vision Center located about 3 blocks from the Duke eye Center.

Their address is 2817 Erwin Road, Durham, NC.  Contact Lynn Shields at 919-973-0763, They are planning a big Open House on Oct 26, Thursday from 5:30 to 7:30 pm.

Besides a nice display of low vision AT equipment, they will soon have the Aira glasses to demonstrate.

The space is available for classes and other LV events.

Contact Lynn to RSVP to attend the Open House.

Lauren Tappan

AMD Project in EU

September 30, 2017

5-year project aims to reduce the disease burden of age-related macular degeneration in Europe and worldwide.

A new European-wide project involving researchers from City, University of London aims to develop new tests and therapies for age-related macular degeneration (AMD).

The MACUSTAR project, which involves several European universities, medical-technology and pharmaceutical companies, will develop these clinical tests and therapeutic options over the course of the 5-year project to help reduce the disease burden of AMD in Europe and worldwide. The project is funded with 16 million euros and is being led by the University of Bonn, Germany.

MACUSTAR is the first exclusively eye disease-focused project approved by the Innovative Medicines Initiative (IMI), Europe’s largest public-private initiative aiming to speed up the development of better and safer medicines for patients.

Central to MACUSTAR is the development of a series of tests for worsening of AMD using state of the art imaging techniques, vision testing and patient reported outcome measures. The main idea is to test these novel approaches to see if subtle changes in AMD can be accurately detected over time. If this is achieved then it will lead to more efficient clinical trials for new treatments for AMD and accelerate drug development. The main costs for the MACUSTAR project are for a huge observational clinical study to be conducted in more than 700 AMD patients from 20 clinical sites across Europe.

For more info:



Blood test for macular degeneration

September 23, 2017

Researchers at Massachusetts Eye and Ear have discovered a group of metabolites that could be used to improve the diagnosis and treatment of AMD.

The Massachusetts Eye and Ear team studied metabolites, or small molecules in the blood of patients with early, intermediate and late-stage AMD, as well as from individuals without AMD.

They found 87 metabolites that were “significantly different” in people with AMD and those without. These molecules also differed between patients with different stages of AMD. This method, dubbed “metabolomics,” could enable the early diagnosis of AMD, allow doctors to personalize treatment for each patient and highlight potential new targets for treatments. The work is published in the journal Ophthalmology, sited below.

For more info:



Enchroma – Color for the Colorblind

September 23, 2017

Introducing Enchroma glasses, a marriage of color vision science and optical technology.
The only specialty eyewear that alleviates red-green color blindness, enhancing colors without the compromise of color accuracy.


A person with red-green color blindness sees the world differently. Their red and green photopigments have more overlap than normal, making them unable to see certain colors. Enchroma found a way to alleviate this by creating a specialized lens that filters out specific colors.


Creating the lens started out as computer simulations, constructing sophisticated models that simulated colors and the extent of color vision deficiency. To create this model, Enchroma utilized the latest research on the genetics of color blindness and various anomalies related to photopigments, and linked these into a model where it gives the effect on how people with red or green color blindness perceive colors.

The second step was to solve the problem by designing an optimal filter, targeting specific photopigments. Enchroma created a (patent pending) method called ‘multinotch’ filtering, cutting out sharp wavelengths of light to enhance specific colors. Enchroma lenses separate the overlapping red and green cones, helping improve vision for people who have difficulty seeing reds and greens.


for more info: